Evaluating DNA methylation episignatures as a first-tier diagnostic test in individuals with suspected genetic disorders
- 3 October 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (2) , 296-299
Abstract
DNA methylation (DNAm) episignature analysis is an emerging tool for diagnosing individuals with neurodevelopmental disorders, congenital anomalies, and growth disorders. We evaluated its clinical utility as a first-tier test in 62 individuals without prior molecular testing. DNAm arrays identified a diagnosis in 30.6% (19/62) of cases. The positivity rate was highest for Fragile X syndrome (100%, 5/5), followed by syndromic disorders (44%, 8/18) and imprinting disorders (25%, 6/24), including Silver-Russell, Beckwith-Wiedemann, and Prader-Willi syndromes. No diagnoses were made in 15 individuals with non-syndromic neurodevelopmental disorders. Alternative diagnoses were identified in 4.8% (3/62) of cases. These findings suggest that DNAm arrays can serve as an effective first-tier diagnostic tool, particularly for syndromic and imprinting disorders, with potential to improve diagnostic efficiency and reduce reliance on sequential genetic testing. While these findings support the use of DNAm arrays as an effective first-tier tool in selected populations, larger, unselected cohort studies are needed to validate its generalizability.Keywords
This publication has 12 references indexed in Scilit:
- DNA methylation episignature testing improves molecular diagnosis of Mendelian chromatinopathiesGenetics in Medicine, 2022
- Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental DisordersThe American Journal of Human Genetics, 2021
- Clinical epigenomics: genome-wide DNA methylation analysis for the diagnosis of Mendelian disordersGenetics in Medicine, 2021
- Functional annotation of genomic variation: DNA methylation episignatures in neurodevelopmental Mendelian disordersHuman Molecular Genetics, 2020
- Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental DisordersThe American Journal of Human Genetics, 2020
- Genome-wide methylation profiling of Beckwith-Wiedemann syndrome patients without molecular confirmation after routine diagnosticsClinical Epigenetics, 2019
- Characterization of multi-locus imprinting disturbances and underlying genetic defects in patients with chromosome 11p15.5 related imprinting disordersEpigenetics, 2018
- Genomic DNA Methylation Signatures Enable Concurrent Diagnosis and Clinical Genetic Variant Classification in Neurodevelopmental SyndromesThe American Journal of Human Genetics, 2018
- Clinical Validation of Fragile X Syndrome Screening by DNA Methylation ArrayThe Journal of Molecular Diagnostics, 2016
- Comprehensive Evaluation of the Child With Intellectual Disability or Global Developmental DelaysPediatrics, 2014